In this note, I detail some common elements of the bear thesis, as well as the counterarguments to this thesis.

Low compliance serves as a risk to consensus estimates, which suggest high growth rates after label expansion approval

Additionally, several competitors are expected to see trial readouts over the coming months

Finally, ongoing patent litigation could pose a risk to longer-term estimates

Bulls posit that compliance is not a significant issue, that competitors lack CV outcome results or a clean safety profile, and that patent litigation is in Amarin’s favor.